Cumberland Pharmaceuticals INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Cumberland Pharmaceuticals Director Martin S. Brown Jr. acquired 1,800 shares of common stock at $2.80 per share.
NASDAQ
Cumberland Pharmaceuticals Director Joseph C. Galante acquired 1,800 shares of common stock, increasing his beneficial ownership.
NASDAQ
Cumberland Pharmaceuticals Director James Jones acquired 1,800 shares of common stock, increasing his beneficial ownership.
NASDAQ
Cumberland Pharmaceuticals Director Kenneth Krogulski acquired 5,800 shares of common stock at $2.80 per share, increasing his direct beneficial ownership to 302,338 shares.
NASDAQ
Cumberland Pharmaceuticals Director Caroline Young reported a planned acquisition of 1,800 shares of common stock at $2.80 per share.
NASDAQ
Cumberland Pharmaceuticals' Vice President of Organizational Development, Todd M. Anthony, acquired 3,000 stock options at an exercise price of $2.80.
NASDAQ
Cumberland Pharmaceuticals' Vice President of Sales & Marketing, Chris T. Bitterman, acquired 3,000 stock options at an exercise price of $2.80.
NASDAQ
Cumberland Pharmaceuticals' VP Chief Financial Officer, John M. Hamm, acquired 3,000 stock options with an exercise price of $2.80.
NASDAQ
James L. Herman, VP and Chief Compliance Officer of Cumberland Pharmaceuticals Inc., acquired 2,500 stock options with an exercise price of $2.80.
NASDAQ
Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, reported the acquisition of 100,000 stock options at an exercise price of $2.80.
NASDAQ
Cumberland Pharmaceuticals Director Caroline Young acquired additional common stock through a pre-arranged 10b5-1 trading plan in December 2025.
NASDAQ
Form 4: Director Jones Boosts CPIX Stake
Cumberland Pharmaceuticals Director James Jones acquired additional common stock through a pre-arranged 10b5-1 trading plan in December 2025.
NASDAQ
Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, acquired additional common stock through a pre-arranged 10b5-1 trading plan throughout December 2025.
NASDAQ
Cumberland Pharmaceuticals Director Kenneth Krogulski acquired 1,916 shares of common stock in December 2025 through a pre-arranged 10b5-1 trading plan.
NASDAQ
Cumberland Pharmaceuticals Director Caroline Young acquired common stock through a pre-arranged Rule 10b5-1 trading plan in November 2025.
NASDAQ
Cumberland Pharmaceuticals Director James Jones acquired additional common stock through a pre-arranged 10b5-1 trading plan.
NASDAQ
Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, acquired additional common stock through a pre-arranged 10b5-1 trading plan in November 2025.
NASDAQ
Cumberland Pharmaceuticals Director Kenneth Krogulski acquired 2,247 shares of common stock through a pre-arranged 10b5-1 trading plan in November 2025.
NASDAQ
Cumberland Pharmaceuticals Director Caroline Young acquired additional common stock through a pre-arranged 10b5-1 trading plan in October 2025.
NASDAQ
Cumberland Pharmaceuticals Director James Jones acquired additional common stock through a pre-arranged 10b5-1 trading plan throughout October 2025.
NASDAQ
Cumberland Pharmaceuticals Inc. Chairman and CEO A.J. Kazimi acquired additional shares of common stock through a pre-arranged 10b5-1 trading plan.
NASDAQ
Cumberland Pharmaceuticals Director Kenneth Krogulski acquired additional common stock through a pre-arranged 10b5-1 trading plan in October 2025.
NASDAQ
Cumberland Pharmaceuticals Director Caroline Young acquired additional common stock through a pre-arranged 10b5-1 trading plan in September 2025.
NASDAQ
Cumberland Pharmaceuticals Director James Jones increased his direct beneficial ownership of common stock through a series of purchases under a Rule 10b5-1 plan.
NASDAQ
Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, increased his direct ownership of common stock through a series of pre-scheduled purchases under a Rule 10b5-1 plan.
NASDAQ
Cumberland Pharmaceuticals Director Kenneth Krogulski acquired additional common stock through a pre-arranged 10b5-1 trading plan in September 2025.
NASDAQ
Cumberland Pharmaceuticals Director Caroline Young acquired additional common stock through a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Cumberland Pharmaceuticals Director James Jones acquired additional common stock through a pre-arranged 10b5-1 plan in August 2025.
NASDAQ
Cumberland Pharmaceuticals Inc.'s Chairman and CEO, A.J. Kazimi, acquired additional common stock through a pre-arranged 10b5-1 trading plan.
NASDAQ
Cumberland Pharmaceuticals Director Kenneth Krogulski acquired additional common stock through a pre-arranged 10b5-1 trading plan.